Marinus Pharmaceuticals
A specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $151m Valuation: $151m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 793 % | 66 % | 22 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (73 %) | (145 %) | - | (3954 %) | (627 %) | (23 %) | (405 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (74 %) | (144 %) | - | (3928 %) | (644 %) | (78 %) | (456 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 49 % | 111 % | - | 2975 % | 479 % | 314 % | 321 % |
Source: Company filings or news article
Related Content
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing ganaxolone, a novel therapeutic aimed at treating seizure disorders. The company primarily serves both adult and pediatric patients suffering from acute and chronic conditions such as refractory epilepsy, status epilepticus, and other seizure-related disorders. Operating within the biopharmaceutical market, Marinus leverages its innovative science pipeline to bring new treatment options to patients who have limited alternatives. The business model revolves around the clinical development, regulatory approval, and subsequent commercialization of ganaxolone. Revenue is generated through the sale of this medication upon approval and market entry. Marinus aims to address unmet medical needs by providing a treatment that offers a new mechanism of action with safe and convenient dosing. The company is committed to improving patient outcomes and enhancing quality of life for those affected by severe seizure conditions.
Keywords: ganaxolone, seizure control, refractory epilepsy, status epilepticus, pediatric care, biopharmaceutical, clinical-stage, novel therapeutics, patient outcomes, chronic conditions.